A randomized phase III trial of BIBW 2992 versus chemotherapy as first-line treatment for stage IIIB/IV adenocarcinoma of the lung harboring an epidermal growth factor receptor-activating mutationJuly 1, 2010
Farletuzumab (MORAb-003) in platinum-sensitive ovarian cancer patients experiencing a first relapseApril 1, 2010Gynecologic Cancer
